APRE

Aprea Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · atrinpharma.com

$0.84

Mkt Cap $5.5M

52w Low $0.55 17.5% of range 52w High $2.22

50d MA $0.82 200d MA $1.16

P/E (TTM) -0.4x

EV/EBITDA 0.7x

P/B 0.4x

Debt/Equity 0.0x

ROE -101.3%

P/FCF -0.4x

RSI (14) —

ATR (14) —

Beta 1.57

50d MA $0.82

200d MA $1.16

Avg Volume 2.3M

About

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 16, 2026	AMC	-0.38	-0.32	+15.8%	0.76	+0.5%	+3.5%	-3.3%	+1.0%	+0.8%	-9.8%	—
Nov 12, 2025	AMC	-0.11	-0.47	-327.3%	1.26	-2.4%	-5.6%	-4.0%	-5.6%	-5.6%	-4.8%	—
Aug 12, 2025	AMC	-0.77	-0.53	+31.2%	1.70	-2.4%	+0.6%	-0.6%	-0.6%	-2.9%	-6.5%	—
May 14, 2025	AMC	-0.65	-0.66	-0.9%	1.53	+3.3%	+17.6%	+21.6%	+20.3%	+14.4%	+4.6%	—
Mar 25, 2025	AMC	-0.69	-0.49	+29.0%	2.19	+2.7%	+2.3%	+0.5%	-4.6%	-6.8%	-12.3%	—
Nov 7, 2024	AMC	-0.75	-0.64	+14.7%	3.98	-2.8%	-10.8%	-11.6%	-13.8%	-17.1%	-15.8%	—
Aug 12, 2024	AMC	-0.64	-0.58	+9.4%	3.22	-0.3%	+2.5%	+0.9%	+5.9%	+18.0%	+17.7%	—
May 14, 2024	AMC	-0.78	-0.67	+14.1%	5.89	-0.3%	-1.5%	-5.1%	-10.5%	-10.4%	-13.4%	—
Mar 26, 2024	AMC	-0.56	-0.92	-64.3%	5.92	+6.6%	+2.5%	+13.0%	+7.3%	+11.5%	+12.7%	—
Nov 9, 2023	AMC	-1.08	-0.86	+20.4%	4.05	-5.6%	-5.2%	-1.5%	+1.2%	-1.2%	-7.4%	—
Aug 10, 2023	AMC	-1.43	-0.87	+39.2%	3.98	+3.0%	+0.5%	-3.3%	-8.8%	-9.5%	-9.5%	—
May 15, 2023	AMC	-1.51	-1.34	+11.3%	3.66	+8.7%	+6.3%	+4.9%	+2.2%	+4.9%	+2.5%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 31	Wedbush	Maintains	Outperform → Outperform	—	$0.74	$0.69	-6.0%	+3.2%	-4.8%	-3.2%	-5.4%	-3.8%
Mar 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.74	$0.69	-6.0%	+3.2%	-4.8%	-3.2%	-5.4%	-3.8%
Feb 10	Wedbush	Maintains	Outperform → Outperform	—	$0.66	$0.66	+0.0%	-3.0%	-7.1%	-10.2%	-7.7%	-9.1%
Jan 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.76	$0.76	-0.5%	-22.8%	+4.2%	-1.7%	-11.9%	-12.3%
Dec 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.91	$0.91	-0.0%	-0.0%	+2.2%	+2.3%	+4.6%	+4.5%
Jan 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.62	$3.53	-2.5%	+1.4%	+3.6%	+6.4%	+11.9%	+10.8%
Dec 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.26	$3.20	-1.8%	+2.5%	-5.5%	-0.9%	-6.4%	-11.0%
Nov 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.25	$3.08	-5.2%	-8.3%	-7.1%	-7.4%	-10.2%	-11.4%
Oct 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.90	$3.90	+0.0%	+0.0%	+4.6%	+9.7%	+9.0%	+2.8%
Aug 13	Wedbush	Maintains	Outperform → Outperform	—	$3.22	$3.21	-0.3%	+2.5%	+0.9%	+5.9%	+18.0%	+17.7%
Aug 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.36	$3.25	-3.3%	-4.2%	-1.8%	-3.3%	+1.5%	+13.1%
Jun 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.01	$4.01	+0.0%	+3.2%	+3.5%	+0.2%	+2.0%	+1.5%
Jun 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.41	$4.30	-2.5%	-4.8%	-7.7%	-7.7%	-9.1%	-6.1%
May 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.59	$5.54	-0.9%	+5.4%	+3.8%	+0.0%	-5.7%	-5.5%
Mar 27	Wedbush	Maintains	Outperform → Outperform	—	$5.92	$6.31	+6.6%	+2.5%	+13.0%	+7.3%	+11.5%	+12.7%
Mar 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.08	$6.04	-0.7%	-2.6%	-0.2%	+10.0%	+4.4%	+8.6%
Nov 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.36	$3.39	+0.9%	+3.0%	+6.0%	+19.0%	+19.0%	+22.3%
Sep 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.02	$4.10	+2.0%	+0.7%	-0.5%	-0.5%	+2.2%	+2.0%
Aug 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.88	$3.93	+1.3%	+2.6%	+3.1%	-0.8%	-6.4%	-7.2%
May 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.66	$3.98	+8.7%	+6.3%	+4.9%	+2.2%	+4.9%	+2.5%
Mar 10	Maxim Group	Maintains	Buy → Buy	—	$5.08	$5.15	+1.4%	-0.8%	+0.6%	+2.0%	+2.8%	+1.4%
Jul 8	Wedbush	Maintains	Outperform → Outperform	—	$16.00	$20.00	+25.0%	+18.8%	+12.5%	+18.2%	+24.1%	+30.0%
Mar 16	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$34.80	$35.20	+1.1%	+14.4%	+4.6%	+4.0%	+4.6%	+4.6%
Mar 16	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$34.80	$35.20	+1.1%	+14.4%	+4.6%	+4.0%	+4.6%	+4.6%
Aug 20	JP Morgan	Downgrade	Neutral → Underweight	—	$68.60	$68.00	-0.9%	+3.5%	+8.7%	+18.4%	+16.0%	+22.2%
Aug 16	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$73.00	$71.80	-1.6%	-2.7%	-2.7%	-0.8%	-6.0%	-2.7%
Aug 16	Berenberg	Downgrade	Buy → Hold	—	$73.00	$71.80	-1.6%	-2.7%	-2.7%	-0.8%	-6.0%	-2.7%
Aug 13	Morgan Stanley	Downgrade	Equal Weight → Underweight	—	$80.80	$75.00	-7.2%	-9.7%	-12.1%	-12.1%	-10.4%	-15.1%
Aug 13	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$80.80	$75.00	-7.2%	-9.7%	-12.1%	-12.1%	-10.4%	-15.1%
Mar 17	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$123.00	$113.00	-8.1%	-3.6%	-5.7%	-7.3%	-9.1%	-15.3%
Dec 29	RBC Capital	Downgrade	Outperform → Sector Perform	—	$110.00	$113.60	+3.3%	-8.2%	-7.8%	-10.5%	-14.0%	-10.9%
Dec 16	Berenberg	Maintains	Buy → Buy	—	$594.60	$595.00	+0.1%	-4.4%	-7.1%	-12.8%	-13.2%	-8.1%
Dec 16	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$594.60	$595.00	+0.1%	-4.4%	-7.1%	-12.8%	-13.2%	-8.1%
Nov 25	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$493.20	$492.40	-0.2%	-2.7%	+7.3%	+2.4%	-0.3%	-0.9%
Jun 22	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$758.00	$738.00	-2.6%	+4.4%	+4.7%	+2.4%	+3.7%	+1.1%
Apr 21	Baird	Maintains	Outperform → Outperform	—	$664.80	$664.00	-0.1%	+2.3%	+1.9%	+1.6%	+1.5%	+0.9%
Apr 15	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$678.40	$672.40	-0.9%	+0.2%	+0.3%	+0.2%	-2.0%	+0.2%
Mar 27	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$637.20	$627.60	-1.5%	+9.1%	+5.1%	+9.1%	+1.3%	+2.0%

Recent Filings

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

Aprea secured funding to accelerate APR-1051 development into broader patient populations, improving pipeline momentum and reducing near-term cash burn concerns for this precision oncology company.

Apr 1

8-K · 1.01 ! Medium

Unknown — 8-K 1.01: Equity Issuance

Aprea Therapeutics is raising capital through an equity offering with Oppenheimer, diluting existing shareholders but providing cash for clinical development and operations.

Mar 30

8-K · 8.01 !! High

Unknown — 8-K 8.01: Material Event / Announcement

I cannot provide meaningful analysis based on this filing excerpt, as it contains only signature blocks without disclosed material events or substantive information about Apre's business developments.

Mar 16

8-K · 8.01 !! High

Aprea Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement

Aprea Therapeutics reported a second unconfirmed partial response in its Phase 1 study of WEE1 inhibitor APR-1051, suggesting potential clinical efficacy in advanced solid tumor patients.

Feb 18

Data updated apr 24, 2026 6:34pm · Source: massive.com